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Protease Activated Receptor 1 (PAR1), a G-protein coupled receptor that is stimulated via 
thrombin-mediated proteolytic cleavage, is implicated in promoting metastasis in a variety of 
tumor types, including both carcinomas and sarcomas. The molecular mechanisms underlying 
PAR1-driven tumor metastasis remain largely unknown. Our laboratory previously discovered 
that PAR1 stimulation in endothelial cells leads to activation of the NF-κB transcription factor, 
and this is mediated by a protein complex comprised of the CARMA3 scaffolding protein, the 
Bcl10 adaptor protein, and the protease MALT1 (CBM). Given the strong association between 
NF-κB and tumor metastasis, we hypothesized that this CBM complex also mediates PAR1-
driven, NF-κB-dependent tumor metastasis. In support of our hypothesis, we demonstrated that 
PAR1 stimulation in both osteosarcoma and in breast cancer cells results in NF-κB activation. 
siRNA-mediated MALT1 knockdown suppresses this NF-κB activation, suggesting that an intact 
CBM complex is required for PAR1-induced NF-κB activity in both tumor cell types. We 
identified several metastasis-associated genes that are significantly upregulated after PAR1 
stimulation of osteosarcoma cells, and found that expression of the matrix remodeling protein 
MMP9, and the inflammatory cytokine IL-1β are both abrogated by MALT1 knockdown. We 
identified a similar, though distinct, PAR1-induced, MALT1-dependent gene expression profile 
in breast cancer cells. We next used CRISPR/Cas9 to knock out MALT1 in MCF7 breast cancer 
cells engineered to express PAR1 (MCF7-N55). In contrast to control MCF7 cells, which do not 
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express PAR1, MCF7-N55 cells are highly invasive in vitro and in vivo. We found that MALT1 
knockout significantly blunts MCF7-N55 invasion and metastasis. Excitingly, we demonstrate 
that PAR1 stimulation induces MALT1 proteolytic activity in both osteosarcoma and breast 
cancer cells. Several small molecule MALT1 protease inhibitors have recently been described, 
and our study suggests that MALT1 could represent a promising new pharmaceutical target for 
the prevention/treatment of PAR1-driven tumor metastasis. 
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1.0  INTRODUCTION 
1.1 DISSEMINATION OF CANCER: METASTASIS 
The first known description of a cancer patient dates to the Edwin Smith papyrus of 1600 BC, 
over one thousand years before the time of Hippocrates, and itself thought to be a copy of a 
document from approximately 3000 BC1.  While examples of disseminated cancer can be found 
throughout history2, an understanding of cancer’s propensity to spread throughout the body only 
began to emerge in the 19th century AD.  First identified as “metastasis of milk,” in the 17th and 
18th centuries the term metastasis was applied to any affliction that appeared to transpose from 
one point of origin to another organ in the body (for a later-period example, see3).  Only in 1829 
did the French surgeon and gynecologist Joseph-Claude-Anthelme Récamier publish his 
Research on the Treatment of Cancer in which “metastasis” was used to refer to the 
dissemination and spread of cancer for the first time4.  One of the pioneers of oncology, 
Récamier concludes his writing with a statement5, the sentiment of which is no less true almost 
two hundred years after his work, and to which the author of this dissertation also aspires: 
 
I will be happy if my work, imperfect as it is, may aid only one other 
observer, to discover the best way to cure the appalling disease which has 
been my particular concern for many years. 
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1.1.1 General mechanisms of cancer metastasis 
Over a century and a half of oncology research has shed an amount of light onto the process by 
which cancer spreads throughout the body.  The picture of metastasis that has emerged is one of 
a highly complex and organized series of steps that requires precise genetic control of 
metastasizing cancer cells in order for distant colonization to be successful6-12.  Further, it is 
becoming increasing clear that metastasis is not a cancer cell-intrinsic process, and the 
contributions of the origin tumor microenvironment as well as the pre-metastatic site niche are 
being recognized as equally important to the process of metastasis13-15.  While the metastatic 
process can be divided into myriad specific steps (Figure 1), it is useful to think of the basic 
process in as simple a fashion as possible, composed of four elements which will be discussed 
below: 
 
1.  Primary tumor invasion and intravasation 
2.  Circulation 
3.  Distal extravasation 
4.  Colonization and proliferation 
1.1.1.1 Primary tumor invasion and intravasation 
Typically, it is thought that cancers are not normally invasive early in the course of the disease.  
Rather, after a period of relatively quiescent growth and proliferation, inflammatory cytokines, 
hypoxia, or numerous other insults induce a transformation from the initial epithelial character of 
the tumor cells to a more aggressive, mesenchymal phenotype, called the Epithelial-
Mesenchymal Transition (EMT)16-18.  EMT is necessary for early steps in metastasis, including 
 3 
tumor cell motility and invasion19.  In this step, tumor cells undergo cytoskeletal reorganization 
into a more elongated, spindle-shaped morphology20.  Additionally, tumor cells undergoing EMT 
display a dramatic change in cell-surface adhesion protein expression.  Cells suppress expression 
of E-cadherin (CDH1), an important factor in adherens junction formation with other cells 
expressing E-cadherin, and gain expression of N-cadherin (CDH2), an adhesion marker 
associated with increased motility in cancer cells21,22. 
In addition to the loss of adhesion proteins, the process of EMT also leads to upregulation 
of matrix remodeling enzymes such as Matrix MetalloProteinases (MMPs) and Urokinase (uPA, 
PLAU)23,24.  These proteins are secreted by tumor cells and are known to play important roles in 
the promotion of cellular motility and tissue invasion (Table 1), as active matrix remodeling 
proteins catalyze the hydrolysis of protein components of the extracellular matrix such as 
collagen25,26.  Degradation of the extracellular matrix allows for tumor cell mobilization and 
invasion into neighboring tissue27. 
Once tumor cells no longer adhere to neighboring cells and also have the capacity to 
degrade the extracellular matrix restricting their motility, the last step of early metastasis is 
intravasation: invasion through a vascular endothelium layer into the vessel lumen and into the 
blood circulation. 
 4 
 
Table 1. Partial list of MMPs with known roles in cancer. 
MMP Cancer References 
MMP1 Breast, ovary 28-31 
MMP2 Breast, fibrosarcoma 32,33 
MMP3 Breast, pancreas 34-37 
MMP7 
Colorectal, bladder, 
esophageal, stomach, 
pancreas, prostate 
38-42 
MMP9 
Breast, stomach, 
melanoma, leukemia 
43-46 
MMP10 Lung, cervix 47-49 
MMP11 
Breast, prostate, 
stomach 
50,51 
MMP12 Lung, squamous cell 52,53 
MMP13 Breast, colorectal 54-57 
 
1.1.1.2 Circulation 
When in the circulation, tumor cells are thought to disseminate as either individual cells or as 
small groups of loosely associated cells58-61.  Normally, non-hematological tissue cells initiate 
apoptosis, programmed cell death, when maintained in anchorage-independent suspension 
without contacts with neighboring cells or extracellular matrix (such as when in the 
circulation)62.  This programmed cell death upon loss of contact with other cells or extracellular 
matrix is termed anoikis63,64.  Anoikis resistance, that is, overcoming anoikis to enable 
anchorage-independent survival within the circulation, is a hallmark of metastatic cancer65.  
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Tumor cells are able to evade anoikis through upregulation of survival associated factors such as 
cIAP2 and Bcl-xL, among other mechanisms66-68. 
1.1.1.3 Distal extravasation 
After entering the circulation, tumor cells must extravasate – exit the vessel lumen through the 
endothelium into the target organ parenchyma – at a site away from the primary tumor.  
Circulating tumor cells appear to lodge in organs with extensive capillary beds or sinuses such as 
the lung, brain, bone, or liver; however, preferential metastasis of some tumor types to specific 
distant organs suggests that the targeting process is not solely mechanical in nature.  Gene 
expression analysis of circulating tumor cells has demonstrated increased expression of tissue-
specific adhesion proteins and homing markers such as CXCR469-72. 
Emerging evidence suggests that distant communication between the primary tumor and 
metastatic target organ induces “pre-metastatic niche” formation in the future metastatic site13,14.  
Primary tumor secreted factors such as cytokines, cellular debris, and extracellular vesicles 
contribute to target organ microenvironmental changes that support metastatic colonization and 
growth15,73.  Formation of a pre-metastatic niche is associated with vascular endothelium 
disruption, extracellular matrix remodeling, and inflammation: processes that enhance the ability 
of circulating tumor cells to successfully extravasate and grow in that site14. 
1.1.1.4 Colonization and proliferation 
After circulating tumor cells have landed in distal sites and exited the circulation, the final step in 
metastasis is the tissue invasion, growth, and proliferation necessary to form a metastatic nodule.  
Importantly, there appears to be a selection gate separating initial micrometastatic growth from 
mature metastatic growth: for micrometastases to grow sufficiently into full-on metastatic 
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nodules, a number of growth-limiting hurdles must be overcome.  Metastases that are to grow 
beyond a small size must initiate tumor angiogenesis to ensure a supply of oxygen and nutrients.  
Indeed, suppression of pro-angiogenic factors in tumor cells has been shown to decrease 
metastatic proliferation in sarcoma, breast cancer, and other tumor types74-76.  In addition to the 
growth limitations imposed by angiogenesis requirements, the metastatic tumor 
microenvironment can inhibit or permit the proliferation of nascent metastases.  Stromal cells 
and extracellular matrix can provide growth suppressing signals to dividing metastatic cells 
which must be overcome in order to successfully colonize the metastatic site77-79.  The 
development of drugs that target the tumor microenvironment in an effort to make it even more 
anti-tumorigenic is an area of active clinical research interest80,81. 
 
 
Figure 1 – Steps in metastasis.  Primary tumor cells undergo EMT and invade into surrounding tissue.  
Invading tumor cells intravasate into the vessel and gain access to the circulation.  Tumor cells survive in circulation 
by suppressing anoikis; distal extravasa 
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1.1.2 Prognosis and treatment of metastatic disease 
The past decades have witnessed substantial gains in the survival of cancer patients with local or 
regional disease; however, effective treatment of metastatic cancer remains a major challenge.  
Formation of distant metastases confers poor prognosis for most types of malignancy, and, for 
many cancers, 5-year survival of patients with metastatic disease at presentation has not 
improved or has even decreased in the last 10 years (Figure 2)80.  For breast cancer and 
osteosarcoma, development of distant metastases drastically worsens prognosis.  Despite 
intensive study, the molecular mechanisms underlying tumor cell dissemination, as well as 
colonization of and growth in distant sites, are very poorly understood (reviewed in9).  
Elucidation of the cellular processes that drive metastasis could result in the discovery of new 
treatments that specifically target pathways promoting metastasis.  Targeted therapeutic 
strategies preventing or treating metastases thus have tremendous potential to lead to significant 
gains in cancer patient survival.  
The disseminated nature of metastatic disease favors systemic therapeutic modalities such 
as chemotherapy in combination with localized treatments such as surgical resection or radiation 
therapy.  Standards of clinical care for both osteosarcoma and breast cancer will be discussed 
below. 
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Figure 2 – Solid Tumor Patient Survival.  5-year patient survival of (a) localized  
disease versus (b) metastatic disease for various solid tumors.  Adapted from80. 
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1.1.3 Metastasis in sarcoma: focus on osteosarcoma 
Osteosarcoma is the most common primary bone tumor of children, representing over 50% of 
bone cancers of patients under the age of 20.  With approximately 900 new cases diagnosed in 
the United States per year, it is the fifth most common tumor diagnosed in adolescents82.  
Osteosarcoma is a sarcoma – a tumor derived from cells of mesenchymal origin – characterized 
by the production of osteoid, the organic component of immature bone matrix.  It primarily 
occurs in the long bones of the extremities, usually the tibia or femur83.  The genetic etiology of 
osteosarcoma is not straightforward: no clear genetic lesions have been identified that drive 
osteosarcomagenesis, though the comparatively low number of cases per year has hindered 
search efforts84.  Loss or inactivation of RB1 and TP53 has been demonstrated in instances, 
although 80% of osteosarcoma cases have no clearly driving genetic lesions85.  The strongest risk 
factor for osteosarcoma is prior irradiation from earlier solid tumor therapy.  Osteosarcoma is 
most frequent during the adolescent growth spurt in highly actively growing long bones, leading 
to the current hypothesis is that osteosarcoma occurs in rapidly dividing bone cells that are 
especially sensitive to oncogenic insults or mitotic errors86,87. 
Osteosarcoma is a clear example of a precipitous decline in prognosis associated with 
metastasis.  In osteosarcoma, 5-year survival rates fall to 15 - 30% in patients with metastatic 
disease; whereas 5-year survival rates are 60 – 80% for patients with localized disease88.  Prior to 
the advent of the modern osteosarcoma treatment protocol of adjuvant / neo-adjuvant 
chemotherapy and radical surgical resection, up to 90% of osteosarcoma patients went on to 
develop clinical metastases, usually to the lungs, even after surgery and localized control of their 
osteosarcoma.  This observation led to the hypothesis, later shown to be correct, that most 
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osteosarcoma patients develop subclinical metastases extremely early on in the course of the 
disease89,90. 
Osteosarcoma survival has increased dramatically since the institution of adjuvant / neo-
adjuvant chemotherapy regimens.  The current standardized protocol is the MAP protocol, 
including both adjuvant (postoperative) and neo-adjuvant (preoperative) doxorubicin, cisplatin, 
and high-dose methotrexate91-96.  With the MAP regimen, approximately 60 to 70% of patients 
that present without metastases will go on to be long-term survivors; whereas less than 25% of 
patients that present with clinical metastases will do so. 
1.1.4 Metastasis in carcinoma: focus on breast cancer 
Over one million cases of breast cancer are diagnosed around the world each year.  In the United 
States, breast cancer is the most common cancer diagnosis and the second-highest cause of 
cancer death in women.  Breast cancers generally arise from the ductal tissue of the breast, 
marking them as carcinomas – epithelium-derived neoplasias.  In contrast to osteosarcoma, the 
genetic background of breast cancer points to clear hereditary factors as well as clear drivers of 
tumor growth97.  The estrogen receptor family (ER), progesterone receptor (PR), and human 
epidermal growth factor receptor 2 (HER2) have been shown to drive early breast cancer 
growth98,99.  HER2 amplification defines a molecular subtype of breast cancer, the HER2-
enriched subtype, which accounts for approximately 10% of breast cancer cases100,101.  Broadly 
speaking, ER expression correlates with favorable prognosis; whereas HER2 enrichment and 
triple-negative (ER, PR, and HER2 negative) cancers have the poorest outcomes102.  In addition 
to molecular drivers of early breast cancer, there is a strong hereditary component to breast 
cancer carcinogenesis.  Although only 5 to 10% of breast cancer patients have a hereditary form 
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of the disease, women with deleterious mutations in the tumor suppressors BRCA1 or BRCA2 
have exceedingly high cumulative risks of developing breast cancer by age 70: 65% and 45%, 
respectively103-105. 
Treatment of early breast cancer consists of surgical management (lumpectomy or 
mastectomy and regional lymph node dissection) with radiotherapy for patients at risk of 
recurrence.  Radiation therapy can constitute of a wide variety of specific modalities, including 
external beam therapy and brachytherapy, and is generally indicated for patients with axillary 
lymph node involvement or poor surgical margins106,107.  Detection of breast cancer metastases 
outside of regional lymph nodes defines stage IV cancer, currently considered incurable.  While 
over 90% of patients with early-stage breast cancer survive past five years, patients with stage IV 
breast cancer have a five year survival rate of approximately 20%108. 
1.2 PROTEASE ACTIVATED RECEPTOR 1 
PAR1 is a G-Protein-Coupled Receptor (GPCR) activated by thrombin, a serine protease central 
in the blood coagulation cascade.  Thrombin acts at several points in the coagulation process, 
converting factors V, VIII, XI, and XIII into their active forms109-112.  Thrombin also catalyzes 
the hydrolysis of fibrinogen into insoluble fibrin, the major matrix component of blood clots.  
Thrombin acts upon and activates PAR1 in a manner unique among cell-surface receptors: 
thrombin-mediated proteolysis of the PAR1 N-terminal extracellular domain uncovers a cryptic 
peptide ligand tethered to PAR1 itself113.  After activation by thrombin, this peptide sequence is 
able to dock with the PAR1 extracellular receptor site and induce PAR1 intracellular signaling 
activation.  Notably, this mechanism of action by thrombin is irreversible: PAR1 signaling 
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deactivation is accomplished through vesicular uptake and internalization of activated PAR1 
molecules and subsequent proteasomal degradation and peptide recycling114. 
PAR1 is the best-characterized of a family of protease-activated receptors, encompassing 
PAR1, PAR2, PAR3, and PAR4115.  Thrombin is known to act upon PAR1, 3, and 4.  Notably, 
several other proteases have been shown to activate various members of the PAR family, 
including MMPs and trypsin, though the physiological role of such non-thrombin PAR activation 
is unknown.  Further, PAR family members appear to be able to transactivate other cell surface 
receptors including other PARs and EGFR, though the extent and character of this signaling in 
vivo is currently debated116-118. 
1.2.1 PAR1 in cancer 
PAR1, is implicated in promoting the progression and metastasis119,120 of a wide variety of 
tumors including breast cancer, lung cancer121-123, melanoma124,125, prostate cancer126-128, 
pancreatic cancer129, and multiple subtypes of sarcoma130,131.  Notably, this list of PAR1-driven 
tumor types includes both epithelial tumors, such as breast cancer, and mesenchymal tumors, 
such as osteosarcoma131.  PAR1 is not expressed in normal breast epithelium, but is upregulated 
in invasive breast cancers, a finding that has led several groups to investigate a role for PAR1 in 
breast cancer metastasis.  A recent study demonstrated that ectopic expression of PAR1 in non-
metastatic MCF7 breast cancer cells causes dramatic changes in cell morphology and induces 
aggressive metastatic behavior both in vitro and in vivo29,132.  These findings suggest PAR1-
induced signaling can promote breast cancer metastasis and may represent a novel therapeutic 
target.  In the case of osteosarcoma, an initial study showed that patients with pulmonary 
metastases have significantly higher levels of thrombin in the lungs as compared to patients 
 13 
without metastasis133.  Additionally, studies have demonstrated that thrombin promotes 
osteosarcoma cell migration in vitro134,135, a necessary step in the process of metastasis.  Further, 
thrombin stimulation of PAR1 in osteosarcoma cells induces the expression of extracellular 
matrix remodeling enzymes such as MMPs and the promotion of invasion136.  Similarly, 
inhibition of thrombin signaling by low molecular weight heparin suppressed osteosarcoma 
proliferation137, strongly suggesting a role for PAR1 signaling in the regulation of several steps 
in metastasis in osteosarcoma. 
1.2.2 Coagulation-associated pathology associated with cancer 
It has been observed that cancer patients are at increased risk of developing thrombi – a 
phenomenon known as the “hypercoagulable state of malignancy” – and a major cause of patient 
morbidity and mortality.  Approximately 20% of cancer patients will experience venous 
thromboembolism138; venous thromboembolism in an otherwise healthy patient can be an 
indication of undetected malignancy.  A number of hypotheses have been proposed to account 
for this clinical observation, from prothrombotic factors secreted by tumors to mechanical 
interactions between cancer cells and the extracellular matrix or stromal cells139. 
In osteosarcoma and breast cancer, coagulation-associated pathology appears correlated 
with progression and metastasis.  Hypercoagulability has been noted in osteosarcoma patients140, 
and increased expression of PAR1 has been discovered in primary osteosarcoma cells embedded 
in peri-tumor thrombus137.  Further, osteosarcoma patients with venous thrombi experienced 
poor clinical outcomes relative to patients without thromboembolic events.  Thrombin treatment 
of osteosarcoma136 or breast cancer141 cells in vitro induced invasion and motility.  Suppression 
of thrombin signaling using low molecular weight heparin inhibited osteosarcoma cell growth 
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and invasion in vitro.  Thrombin stimulation of both osteosarcoma and breast cancer cells also 
induced expression of pro-metastatic factors such as MMPs136. 
The mechanisms underlying this prothrombotic state are still under debate, as the 
etiology and incidence of the hypercoagulable state of malignancy appear to be heterogeneous.  
Most cancer cells express Tissue Factor (TF) on their surface, which is capable of converting 
prothrombin to thrombin through the activation of factors IX and X.  Thrombin is a potent 
activator of platelets and can cause platelet aggregation and clot formation.  It has been 
demonstrated that cancer cells can interact with platelets to form small emboli of loose platelet-
tumor cell collections, and that tumor cell interactions with platelets prolong survival in the 
circulation142.  Additionally, platelet-derived growth factors such as Vascular Endothelial 
Growth Factor (VEGF), LysoPhosphatidic Acid (LPA), Platelet-Derived Growth Factor (PDGF) 
are known to promote cancer growth and metastasis.  Tumor-associated hypercoagulability is 
likely a byproduct of the beneficial interactions between tumor cells and activated platelets, at 
least in part. 
1.3 THE CARMA3/BCL10/MALT1 SIGNALING COMPLEX 
The CARMA – Bcl10 – MALT1 (CBM) signaling complex is an intracellular signaling complex 
that is found downstream of a wide variety of cell surface receptors.  The three proteins that 
comprise the core complex itself are described below. 
CARMA – so named as the family contains CARD (caspase activation and recruitment 
domain) and MAGUK (membrane-associated guanylate kinase-like) domains (Figure 2) – is the 
scaffold protein of the complex143.  CARMA phosphorylation by PKC isoforms is required for 
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CBM complex oligomerization into long, signaling-active filaments comprised of many CBM 
heterotrimers144,145.  Notably, there are three CARMA family members that appear to be 
functionally similar, albeit with differing expression patterns: CARMA1 (also commonly known 
as CARD11) is found in hematological and lymphoid cells, CARMA2 (CARD14) is expressed in 
the placenta, and CARMA3 (CARD10) expression is widely distributed in somatic cells146.  
CARMA phosphorylation allows for CBM complex formation and signaling activation. 
Bcl10 is the smallest member of the complex and serves as a linker protein to bring 
phosphorylated CARMA and MALT1 together.  Bcl10 and MALT1 form constitutive 
heterodimers in the cytosol147.  The scope of Bcl10-specific signaling and interactions is 
increasing as Bcl10 has become an independent subject of research interest.  Bcl10 
phosphorylation appears to modulate NF-κB signaling downstream of the CBM complex148, and 
Bcl10 cleavage by MALT1 is still not fully understood, though T cells expressing an uncleavable 
Bcl10 mutant demonstrated impaired adhesion149. 
MALT1 is broadly considered the downstream effector protein of the CBM complex, 
responsible for the propagation of downstream signaling via protein-protein interactions or direct 
proteolytic activity.  It is discussed in detail below. 
Signaling events upstream of the CBM complex were originally worked out in 
lymphocytes with the CARMA1-containing CBM and are presumed to be similar in non-
lymphocytes with the CARMA2- and CARMA3-CBM: PKC activation downstream of cell 
surface receptor ligand binding phosphorylates CARMA.  Different PKC isoforms have been 
found upstream of the CBM complex: PKCβ in B cells and PKCθ in T cells150.  While signaling 
events upstream of the CBM have not been elucidated in non-CARMA1-containing cells, PKC 
agonists such as Phorbol Myristate Acetate (PMA) and ionomycin151 have been shown to 
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activate CBM signaling in CARMA3-containing cells, suggesting that activation of the 
CARMA3-CBM complex is likely similar to that of the CARMA1-CBM coplex152. 
 
 
 
Figure 3 – Domain structure of CARMA3, Bcl10, and MALT1.  Black arrows show regions of 
interaction between proteins.  CARD: Caspase Activation and Recruitment Domain.  SH3: Src-
Homology 3 domain.  GUK: Guanylate Kinase like domain.  Ig: Immunoglobulin domain. 
 
1.3.1 The CARMA1-CBM complex: a history rooted in lymphomagenesis 
The CBM signalosome originally came into the research spotlight when it was noticed that a 
series of chromosomal translocations and abnormalities were associated with the development of 
B cell lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT lymphoma).  MALT 
lymphoma, first detailed in 1983153, is the most common extra-nodal lymphoma, and most 
frequently develops in MALT associated with chronic inflammation such as in the stomach or 
lung.  The t(11;18)(q21;q21) translocation was the first to be described in patients154, although 
discovery of the gene product would occur ten years later: a fusion between Inhibitor of 
Apoptosis 2 (API2, also cIAP2) and MALT1 creating the API2-MALT1 oncoprotein155-157.  
MALT lymphoma with the API2-MALT1 translocation was found to be persist despite H. pylori 
antibacterial treatment158, suggesting that API2-MALT1 conferred inflammation-independent 
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growth of the tumor.  Other translocations were discovered that associated with the development 
of MALT lymphoma.  The t(1;14)(p22;q32) translocation159 was found to move the BCL10 gene 
such that its expression was constitutively driven by the immunoglobulin heavy chain enhancer 
promoter element (IGH-Bcl10)160.  Similarly, the t(14;18)(q32;q21) translocation was 
discovered161 to place the MALT1 gene under the control of the immunoglobulin heavy chain 
enhancer promoter element to make constitutively-expressed IGH-MALT1 in a fashion akin to 
the t(1;14)(p22;q32) translocation that creates IGH-Bcl10162,163. 
After members of the CBM complex were discovered to be targets of chromosomal 
translocation in MALT lymphoma, an inflammation-associated tumor, it rapidly became 
apparent that Bcl10 and MALT1 were intracellular mediators that activated the inflammatory 
transcription factor family NF-κB.  Bcl10 was shown to be necessary for activation of NF-κB in 
mouse T and B cells164, while T cell receptor (TCR) activation of NF-κB was shown to be 
MALT1 dependent165. 
CARMA proteins were added to the emerging model of the CBM complex when a novel 
Bcl10-interacting protein was found to activate NF-κB166,167.  Other CARMA family members 
were rapidly identified168,169, and it was subsequently shown that CARMA proteins interact with 
Bcl10 and MALT1 to activate NF-κB170-172. 
1.3.2 The CARMA3-CBM complex 
Although most early studies of the CBM complex were performed in immune cells and 
examined the CARMA1-containing complex, initial reports suggested that other CARD-carrying 
MAGUK-domain proteins did exist169.  Genetic studies of these other CARMA family members 
showed that knockout of CARMA3 induced an embryonic-lethal neural tube formation defect 
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similar to the one observed in CARMA1 knockout mouse embroys173.  Furthermore, ectopic 
CARMA3 expression rescued NF-κB activation downstream of TCR stimulation in CARMA1-
deficient T cells, strongly suggesting an amount of functional redundancy between CARMA3 
and CARMA1174.  While CARMA3 was found to interact with Bcl10 and MALT1, the context 
of such CARMA3-CBM signaling was not apparent. 
A series of papers published in the Proceedings of the National Academy of Sciences in 
January of 2007 established the current model of the CARMA3-containing CBM complex 
downstream of G-protein coupled cell surface receptors.  All at once, it was discovered that 
CARMA3-CBM complex activated NF-κB downstream of the LPA175, angiotensin II176, and 
endothelin receptors177.  Subsequent studies identified even more cell surface receptors that 
activated NF-κB via the CARMA3-CBM complex, including the CXCL12/SDF-1 receptor 
CXCR4176,178-180, the IL8 receptor CXCR2181, and, most notably, PAR1182.   
1.3.3 MALT1: scaffolding signaling and proteolytic activity 
MALT1, the effector protein of the CBM complex, possesses two distinct functions by which it 
carries out downstream signaling: protein-protein interactions and direct proteolysis by MALT1 
itself. 
Activated MALT1 forms important protein-protein interactions, termed “scaffolding 
signaling” by the field, with components of the NF-κB signaling machinery such as the TRAF6 
ubiquitin ligase183, Linear Ubiquitin Chain Assembly Complex (LUBAC), and kinase TAK1184.  
MALT1 interaction with these intermediates results in IKKγ polyubiquitination and subsequent 
IKK complex phosphorylation and activation185,186.  This active IKK complex induces Inhibitor 
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of κB (IκB) phosphorylation and degradation, leading to translocation of NF-κB transcription 
factor dimers into the nuclear and NF-κB transcriptional activation187. 
In addition the scaffolding signaling capacity of MALT1, it has recently been discovered 
that the paracaspase domain188 (Figure 3) of MALT1 is enzymatically active and that it acts to 
cleave a specific set of protein substrates149,189,190.  Among other substrates, MALT1 cleaves and 
destroys the NF-κB family transcription factor subunit, RelB, and the deubiquitinases, CYLD 
and A20188,190-192 (Table 2).  The effects of MALT1 protease activity on CBM signaling outputs 
are not completely understood, though the current hypothesis is that MALT1 proteolytic activity 
enhances scaffolding signaling.  MALT1 substrates appear to include inhibitors of the NF-κB 
signaling pathway, and thus MALT1 proteolytic activity may serve to maximize MALT1 
scaffolding signaling activation of NF-κB by cleaving and inactivating these inhibitory 
substrates. 
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Table 2. List of known MALT1 substrates and effects of MALT1 proteolysis. 
Substrate Role Effect of MALT1 proteolysis References 
A20 Deubiquitinase NF-κB activation enhancement 190 
RelB Non-canonical NF-κB 
transcription factor 
NF-κB activation enhancement 191 
MALT1 CBM complex protein NF-κB activation enhancement 193 
CYLD Deubiquitinase  
AP-1 transcription factor 
activation, endothelial cell 
permeability 
192,194 
Regnase-1 RNAse 
mRNA stabilization, increased 
mRNA synthesis 
195,196 
Roquin-1/2 mRNA deadenylation 
promoter 
mRNA stabilization 196 
Bcl10 CBM complex protein Reduced leukocyte adhesion 149 
HOIL1 LUBAC subunit NF-κB activation enhancement 197 
 
1.3.4 The role of the CBM complex in solid tumors 
Given the tight association between the CARMA1-CBM complex and lymphoma, it was 
surmised that the CARMA3-CBM complex might play a similarly oncogenic role in solid 
tumors.  Lymphomagenic activating mutations and translocations of the CARMA1-CBM 
complex have been described in the literature and are discussed above.  Somewhat surprisingly, 
no similarly oncogenic mutations or translocations of the CARMA3-CBM complex in solid 
tumors have been discovered to date.  Despite this apparent lack of an observation, it is clear that 
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CARMA3-CBM signaling and activation of NF-κB is important to the development and 
progression of multiple solid tumors, including ovarian cancer, oral squamous cell carcinoma, 
lung cancer, and breast cancer. 
Enrichment of LPA receptors, GPCRs known to act through the CARMA3-CBM 
complex, has been seen in malignant populations of ovarian cancer198.  Additionally, suppression 
of CARMA3, Bcl10, or MALT1 inhibits in vitro invasion of ovarian cancer cells199.  Outside of 
ovarian cancer, MALT1 silencing suppresses CXCR4 stimulation-induced invasion of oral 
squamous cell carcinoma cells180.  Further, in lung cancer, CARMA3 expression correlates with 
poor prognosis, NF-κB activation, and EGFR expression200.  In a subsequent finding, MALT1 
was found to mediate EGFR stimulation-induced NF-κB activation in lung cancer, and 
suppression of MALT1 increased lung cancer anchorage-independent growth and invasion and 
reduced tumor burden in an EGFR-driven model of lung cancer in mice201. 
In breast cancer, the CARMA3-CBM complex has been implicated in mechanisms linked 
to tumor promotion and metastasis.  A recent study demonstrated that CBM-complex mediated 
activation of NF-κB downstream of HER2 stimulation, and that MALT1 knockout delayed 
tumor formation in a mouse model of spontaneous breast cancer with HER2 overexpression202.  
Other studies have implicated the CARMA3-containing CBM complex in NF-κB activation and 
chemotherapeutic resistance in breast cancer cells203. 
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1.4 THE INFLAMMATORY TRANSCRIPTION FACTOR NF-ΚB 
While NF-κB is commonly spoken of as a single transcription factor, in actuality it is a complex 
formed from five separate Rel-homology domain-containing proteins that comprise the NF-κB 
family: RelA (p65), RelB, c-Rel, p50, and p52.  NF-κB members assemble in a wide variety of 
hetero- and homodimers which are then able to bind to NF-κB DNA response elements to 
activate or repress transcription at those sites204,205.  Of these family members, RelA, RelB, and 
c-Rel contain transactivation domains that are necessary for target gene transcription. 
1.4.1 NF-κB signaling: canonical and non-canonical activation 
Canonical – or “classical” – NF-κB activation is defined by IKK complex-mediated 
phosphorylation of IκB.  Upstream signaling events result in IKKγ (NEMO) ubiquitination and 
formation of the active IKK complex, composed of IKKα, IKKβ, and IKKγ206.  The active IKK 
complex phosphorylates IκB at two sites, leading to its ubiquitination by ubiquitin ligases and 
subsequent proteasomal degradation.  Degradation of IκB releases previously-sequestered NF-κB 
transcription factor dimers, which are then free to translocate to the nucleus and bind to NF-κB 
response elements.  Release of RelA/p50 heterodimers is most closely associated with the 
canonical NF-κB pathway207.  
In contrast, non-canonical – or “alternative” – NF-κB signaling results in the nuclear 
translocation and DNA-binding of RelB/p52 complexes.  Receptor stimulation results in 
activation of NF-κB Inducing Kinase (NIK), which then phosphorylates and activates IKKα.  
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Activated IKKα homodimerizes and phosphorylates RelB-bound p100, triggering its proteolytic 
processing into p52.  p100 acts similar to IκB in the classical NF-κB pathway, inhibiting RelB 
translocation to the nucleus and suppressing alternative NF-κB signaling; however, upon 
processing to p52, this inhibition is lost, and RelB/p52 heterodimers are capable of nuclear 
translocation and signaling activation208. 
1.4.2 NF-κB activation in cancer metastasis and progression 
NF-κB activation promotes metastasis and cancer progression via several mechanisms (Figure 
4) 209,210.  First, NF-κB stimulates cell proliferation and protects against apoptosis directly 
through upregulation of a variety of survival factors and tissue invasion effectors, such as cIAP 
and MMPs211.  NF-κB promotes specific aspects of cell survival important to the metastatic 
process: for example, NF-κB promotes survival in the face of cytotoxic chemotherapeutic agents 
(ie chemotherapy resistance) and suppresses anoikis67,212.  Second, NF-κB induction is associated 
with MMP expression and tissue invasion27,213.  Third, NF-κB activation is tightly linked with 
the expression of Epithelial-Mesenchymal Transition (EMT) markers such as Twist and 
Snail214,215.  Fourth, NF-κB signaling has been implicated in the expression of cellular adhesion 
proteins, necessary in the vascular extravasation step of metastasis209.   
In breast cancer patients, NF-κB activation in tumor samples correlates with poor 
prognosis and aggressiveness of disease216,217.  In other studies, NF-κB transcriptional activation 
has been linked to increased cell motility, in vitro invasion, and increased proliferation218.  NF-
κB also plays a role in drug resistance of breast cancer cells: NF-κB activation was found to 
suppress apoptosis in response to chemotherapeutic treatment219, while inhibition of NF-κB 
dramatically increased breast cancer sensitivity to chemotherapeutic agents in vitro220.  
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Furthermore, an apparent population of breast cancer stem cells or tumor-initiating cells requires 
NF-κB activation in order to continue self-renewal of stem cell capacity221. 
In osteosarcoma, pharmacological NF-κB suppression has been shown to reduce tumor 
volume of osteosarcoma xenografts222 as well as spontaneous metastasis of orthotopically 
injected tumor cells to the lungs in murine models223.  Additionally, genetic suppression of NF-
κB has been shown to markedly decrease pulmonary metastasis in mouse models and reduce 
tumor angiogenesis224. 
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Figure 4 – Roles of NF-κB in cancer metastasis.  The NF-κB transcription factor family is implicated in many 
steps of metastasis. 
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1.5 HYPOTHESIS 
While PAR1 has been shown to be important in driving tumor metastasis in a wide variety of 
contexts in multiple studies, the precise molecular mechanisms underlying this effect are unclear.  
We hypothesize that PAR1 induced CBM-mediated NF-κB activation promotes tumor 
invasion and metastasis, and in this study we specifically test this hypothesis using both 
breast cancer and osteosarcoma model systems (Figure 5).  Our analysis of the signaling 
events responsible for NF-κB transcriptional activation and promotion of metastasis in these 
cancers has great potential to lead to the identification of novel future therapeutic targets.  For 
example, MALT1 proteolytic activity inhibitors are currently under development and may prove 
to be effective in preventing and/or treating PAR1-driven tumor metastasis. 
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Figure 5 – Hypothesis.  The CBM complex mediates PAR1 activation of NF-κB and subsequent 
pro-metastatic effects in solid tumors. 
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2.0  RESULTS 
2.1 TUMOR PAR1 EXPRESSION PREDICTS CLINICAL OUTCOME IN 
OSTEOSARCOMA AND BREAST CANCER 
2.1.1 Osteosarcoma 
We explored available clinical datasets in order to assess whether tumor expression of PAR1 
correlates with clinical outcome and presence of tumor metastases.  We first studied 
osteosarcoma using a published clinical case series in which patient tumor sample gene 
expression profiles were examined225.  The authors of this study harvested primary tumor 
samples and assessed gene expression using mRNA microarrays.  Sorting cases according to 
PAR1 (F2R) gene expression revealed a significant survival advantage for patients with tumors 
that expressed low levels of PAR1 (Figure 6a).  Median survival time of high-PAR1 cases was 
approximately 60 months; whereas median survival time for patients with low tumor PAR1 
expression was approximately 120 months.  Due to the low number of osteosarcoma cases 
available for study (n = 46), high PAR1 expression was defined as above-median tumor PAR1 
expression, while low PAR1 expression was set as below-median tumor PAR1 expression. 
We also studied whether patients that died during the study period showed any difference 
in tumor PAR1 expression relative to patients who survived.  While patients that died during the 
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study appeared to have somewhat higher levels of tumor PAR1 expression over surviving 
patients (Figure 6b), the low number of osteosarcoma cases available did not allow for sufficient 
power to state that the result was significant at an alpha of 0.05 (Student t test).   
 
 
 
Figure 6 – PAR1 expression is associated with poor clinical outcome and increased tumor 
metastasis in osteosarcoma. (a) Kaplan-Meier survival plot of osteosarcoma patients sorted by high 
(above median) and low (below median) PAR1 expression in tumor samples. (b) Expression of PAR1 
in osteosarcoma patient tumor samples by survival status; this result is not statistically significant, 
likely due to the low number of cases analyzed (n = 46). Data are from Kelly et al.225.  
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2.1.2 Breast cancer 
We also examined the relationship between tumor PAR1 expression and survival in breast 
cancer.  Using data from The Cancer Genome Atlas (TCGA)226 – a database containing mRNA 
microarray and next-generation exome sequencing expression data – we observed that PAR1 
expression negatively correlates with survival in stage 3 breast cancer patients (Figure 7a).  
Patients with high tumor PAR1 expression show significantly greater rates of mortality and did 
not live as long as patients with low PAR1 (median survival of approximately 100 months vs. 
>300 months).  Given the greater number of breast cancer clinical cases available for study (n = 
723), high PAR1 was defined as the patients in the top quartile of tumor PAR1 expression; 
whereas low PAR1 was set as the patients in the bottom quartile. 
Additionally, we found a strong positive relationship between tumor PAR1 expression 
and the number of metastasis-positive lymph nodes (Figure 7b).  Patients with no lymph node 
metastases had significantly (p < 0.05) lower levels of primary tumor PAR1 expression 
compared with the primary tumor PAR1 expression of patients with the highest number of 
metastasis-positive lymph nodes.  PAR1 expression increased steadily with the number of -
positive lymph nodes. 
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Figure 7 – PAR1 expression is associated with poor clinical outcome and increased tumor 
metastasis in breast cancer.  (a) Kaplan-Meier survival plot of grade 3 breast cancer patients. 
Patients with high (top quartile) tumor PAR1 expression show decreased survival over time 
compared to patients with low (lowest quartile) tumor PAR1 expression. (b) PAR1 expression 
correlates with metastatic lymph node number in breast cancer patients. Data are from the TCGA226. 
*: p < 0.05 
2.2 PAR1 STIMULATION INDUCES NF-ΚB IN OSTEOSARCOMA CELLS 
2.2.1 Osteosarcoma cell line identification 
In light of our observation that PAR1 tumor expression correlates with adverse clinical outcome 
and metastasis, we next wished to investigate the molecular mechanism by which PAR1 
signaling promotes metastasis.  Our laboratory previously discovered that PAR1 stimulation 
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triggers CBM complex-mediated canonical NF-κB activation in vascular endothelial cells182.  
We thus tested whether similar signaling events also take place downstream of PAR1 stimulation 
in tumor cells.  We utilized data from the Cancer Cell Line Encyclopedia (CCLE)227, a database 
with characterizations of approximately 1000 cancer cell lines, to examine PAR1 expression in 
human osteosarcoma cell lines (Figure 8), and noted that U2OS, a well-studied untransformed 
human osteosarcoma cell line, expresses a relatively high level of PAR1 relative to other 
osteosarcoma lines136.  While other osteosarcoma cell lines showed slightly higher PAR1 
expression, U2OS was the best-characterized line with elevated PAR1 expression.  Additionally, 
we noted that all osteosarcoma cell lines demonstrated some degree of above-median PAR1 
expression, where the median was set at the median expression of PAR1 in all cell lines in the 
CCLE. 
 
Figure 8 – PAR1 expression of osteosarcoma cell lines.  U2OS 
osteosarcoma cells express PAR1. Log(2) median-centered 
expression of PAR1 mRNA in selected osteosarcoma cell lines is 
shown, where the median is median expression of PAR1 in all 
cancer cell lines studied in the CCLE227. 
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2.2.2 U2OS cells activate NF-κB: pIκB, RelA nuclear localization, and luciferase assay 
We then analyzed U2OS cells in vitro by stimulating with two distinct PAR1 agonists: 1) 
thrombin, the natural ligand which stimulates PAR1 as well as the related PAR3 and PAR4228 via 
proteolytic cleavage, and 2) TRAP6, a synthetic peptide ligand (SFLLRN) which specifically 
mimics thrombin-induced PAR1 activation229.  We found that stimulation of U2OS cells with 
either thrombin or TRAP6 induces robust phosphorylation of IκB, a proximal step in NF-κB 
activation (Figure 9a – see section 1.4.1). 
We then examined the steps required for NF-κB activation downstream of IκB 
phosphorylation, and observed that thrombin stimulation of U2OS cells leads to translocation of 
the canonical NF-κB signaling-associated subunit RelA (p65) into the nucleus as shown by 
nuclear fractionation and immunoblot (Figure 9b).  Additionally, thrombin stimulation of U2OS 
cells enhanced RelA DNA binding activity as detected by NF-κB DNA-binding ELISA (Figure 
9c).  Finally, we performed an NF-κB luciferase reporter assay to assay NF-κB-driven 
transcriptional activity downstream of PAR1 stimulation.  U2OS cells stimulated with thrombin 
demonstrated increased luciferase expression relative to cells treated with a vehicle control 
(Figure 9d). 
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Figure 9 – U2OS osteosarcoma cells activate NF-κB in response to PAR1 
agonist stimulation.  (a) Stimulation of U2OS human osteosarcoma cells 
with the 25 μM TRAP6 or 2 U / mL thrombin for 20 minutes induces 
phosphorylation of IκB.  (b) Nuclear fractionation of U2OS cells stimulated 
with 25 μM TRAP6 for 1 hour shows increased nuclear translocation of the 
NF-κB subunit RelA as compared to vehicle control. (c) NF-κB consensus-
sequence DNA ELISA demonstrates that 2 U / mL thrombin stimulation of 
U2OS cells for 3 hours leads to increased RelA DNA binding.  (d) U2OS 
cells transfected with an NF-κB reporter plasmid induce expression of 
luciferase when treated with 2 U / mL thrombin for 8 hours. Data are 
normalized to transfection efficiency using Renila co-transfection. 
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2.2.3 U2OS cells require MALT1 for PAR1-driven NF-κB activation 
We next sought to characterize the specific mechanism by which PAR1 activates NF-κB in 
osteosarcoma cells, asking whether the CBM complex is required for intracellular signal 
transduction.  We performed siRNA knockdown of CARMA3, Bcl10, and MALT1 and found 
that phosphorylation of IκB subsequent to PAR1 stimulation is suppressed in U2OS cells 
transfected with siRNA directed against any constituent of the CBM complex (Figure 10a).  We 
then focused our subsequent efforts on the effector protein, MALT1, and found that siRNA 
suppression of MALT1 completely abrogates TRAP6 or thrombin-induced NF-κB luciferase 
reporter activity (Figure 10b). 
Taken together, these results show that PAR1 stimulation does result in NF-κB 
activation, from phosphorylation of IκB to RelA nuclear localization and transcriptional 
activation, in U2OS human osteosarcoma cells.  Further, this NF-κB activation appears to be 
dependent on the CBM complex, as loss of MALT1 suppresses both phosphorylation of IκB and 
NF-κB transcriptional activity.  
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Figure 10 – PAR1 activation of NF-κB signaling requires the CBM complex in U2OS cells.  (a) PAR1-
induced phosphorylation of IκB in U2OS cells is lost when any member of the CARMA3-Bcl10-MALT1 
(CBM) complex is suppressed using siRNA. Cells were stimulated with 2 U / mL of thrombin for 20 
minutes. (b) siRNA-mediated knockdown of MALT1 suppresses PAR1-induced NF-κB luciferase reporter 
activity. Cells were stimulated with 2 U / mL thrombin for 8 hours. *: p < 0.05. 
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2.3 BREAST CANCER CELLS ACTIVATE NF-ΚB IN RESPONSE TO PAR1 
STIMULATION IN VITRO 
2.3.1 Breast cancer cell line identification 
We then turned to analysis of PAR1 signaling in breast cancer.  In examining CCLE PAR1 
expression data, we found that MDA-MB-231, a highly metastatic human breast cancer cell line 
thought to represent an aggressive subtype of breast cancer, exhibits relatively high endogenous 
PAR1 expression (Figure 11). 
In addition to the MDA-MB-231 human breast cancer cell line, we noted that the human 
breast cancer line MCF7 appeared to have low PAR1 expression (Figure 11).  MCF7 is a well-
studied untransformed non-metastatic human breast cancer cell thought to represent an early-
stage, less aggressive subtype of the disease.  For comparison with the parental MCF7 cell line, 
we obtained the MCF7-N55 cell line.  MCF7-N55 is an engineered derivative of MCF7 in which 
PAR1 has been stably expressed29.  Notably, ectopic PAR1 expression in MCF7 cells causes 
significant morphological and phenotypic alterations: MCF7-N55 cells take on an elongated, 
mesenchymal shape relative to the parental MCF7 line132.  Additionally, MCF7-N55 cells readily 
invade through extracellular matrix in vitro and colonize mouse lungs in vivo in a tail vein 
injection assay of metastasis; whereas MCF7 cells remain quiescent in vitro and do not 
metastasize in vivo29. 
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Figure 11 – PAR1 expression of breast cancer cell lines.  MDA-MB-231 cells express comparatively high 
PAR1; whereas PAR1 levels are low in MCF7 cells.  Log(2) median-centered expression of PAR1 mRNA in 
selected breast cancer cell lines is shown, where the median is median expression of PAR1 in all cancer cell lines 
studied in the CCLE227. 
2.3.2 Breast cancer cells activate NF-κB when stimulated with the PAR1 agonist TRAP6 
Stimulation of MDA-MB-231 cells with either TRAP6 or thrombin induces phosphorylation of 
IκB, indicating activation of canonical NF-κB signaling (Figure 12a).  Additionally, TRAP6 
stimulation of parental MCF7 cells does not result in phosphorylation of IκB, an expected 
finding given the lack of PAR1 expression in these cells (Figure 12b).  Stimulation of MCF7 
cells with TNFa elicited phosphorylation of IκB, indicating that NF-κB induction machinery was 
intact in MCF7.  In contrast, MCF7-N55 cells demonstrate robust phosphorylation of IκB when 
stimulated with TRAP6, as expected given the stable expression of PAR1 in these cells. 
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Figure 12 – Breast cancer cells activate NF-κB in response to PAR1 agonist stimulation.  (a) 
Stimulation of MDA-MB-231 cells with the 50 μM TRAP6 or 2 U / mL thrombin for 15 minutes 
induces phosphorylation of IκB.  (b) PAR1 stimulation with 50 μM TRAP6 fails to induce 
phosphorylation of IκB in MCF7 human breast cancer cells; whereas TRAP6 treatment induces robust 
phosphorylation of IκB in MCF7-PAR1 cells.   
2.3.3 MALT1 is required for PAR1-driven NF-κB activation in breast cancer 
MALT1 knockdown results in loss of IκB phosphorylation in MDA-MB-231 cells stimulated 
with TRAP6 (Figure 13a).  Further, we observed a similar suppression of IκB phosphorylation 
after TRAP6 treatment in MCF7-N55 transfected with siRNA directed against MALT1 (Figure 
13b). 
Taken together, these results indicate that TRAP6 stimulation of the PAR1-expressing 
breast cancer cells MDA-MB-231 and MCF7-N55 induces MALT1-dependent NF-κB 
activation, similar to the results we observed in osteosarcoma cells. 
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Figure 13 – Breast cancer cells require MALT1 in order to activate PAR1 – NF-κB signaling.  (a) PAR1-
induced phosphorylation of IκB in MDA-MB-231 cells is lost when MALT1 is suppressed using siRNA. Cells were 
stimulated with 50 µM TRAP6 for 20 minutes.  (b) PAR1-induced phosphorylation of IκB in MCF7-PAR1 cells is 
lost when MALT1 is suppressed using siRNA. Cells were stimulated with 50 µM TRAP6 for 20 minutes. 
2.4 PAR1 ACTIVATION OF NF-ΚB DRIVES PRO-METASTATIC GENE 
EXPRESSION IN OSTEOSARCOMA 
2.4.1 RT-PCR microarray 
We next asked whether PAR1 stimulation of NF-κB in cancer cells caused gene expression 
reprogramming known to be associated with metastasis.  First, we employed a custom RT-PCR 
microarray to assess changes in the expression levels of genes known to be NF-κB targets and to 
promote metastasis (Figure 14).  Data in Figure 14 are shown as a heat map of relative 
quantification Z-scores across three independent biological replicates: significant upregulation of 
expression is colored red, while blue denotes significant downregulation.  We detected several 
significant gene expression changes in U2OS cells after stimulation with thrombin.  Several 
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metastasis-associated matrix remodeling proteins such as MMP9, 10, and 12 were significantly 
upregulated in thrombin-treated U2OS cells.  We also observed a significant increase in 
expression of the inflammatory cytokine IL1B. 
 
 
Figure 14 – Invasion-associated RT-PCR microarray results.  Heat map of Z-scores for invasion-associated RT-
PCR microarray. U2OS human osteosarcoma cells were stimulated with 2 U / mL thrombin for 6 hours. Three 
biological replicates of the array were performed.  Black: no value returned from replicate (technical error). 
2.4.2 Microarray hits: MMP9 and IL1B 
We then examined whether MALT1 was required for the PAR1-stimulation associated 
upregulation of genes detected in the metastasis-associated RT-PCR microarray in U2OS 
osteosarcoma cells.  We noted that MALT1 loss suppresses thrombin-dependent induction of 
inflammatory cytokine IL1B (Figure 15a).  Additionally, MALT1 is also required for PAR1-
driven upregulation of the matrix metalloproteases MMP9 and MMP12 (Figures 15b and 15c).  
siRNA was used to knock down MALT1; a representative demonstration of MALT1 knockdown 
detected by RT-PCR is shown (Figure 15d).   
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Figure 15 – Upregulation of invasion-associated genes requires MALT1 in osteosarcoma cells.  (a) 
IL1B, (b) MMP9, and (c) MMP12 mRNA expression is induced by stimulation of U2OS cells with 2 U / mL 
thrombin for 6 hours.  (d)  siRNA-directed MALT1 knockdown suppresses PAR1-dependent gene induction.   
2.5 PAR1 DRIVES PRO-METASTATIC GENE EXPRESSION IN BREAST CANCER 
Having identified upregulation of metastasis-associated genes downstream of PAR1 signaling 
activation in osteosarcoma, we next looked at gene expression reprogramming in breast cancer.  
We observed that stimulation of PAR1 in both MDA-MB-231 breast cancer cells and MCF7-
N55 breast cancer cells results in gene expression changes that are similar to, though distinct 
from, those observed in osteosarcoma cells.  In common with U2OS osteosarcoma cells, MDA-
MB-231 and MCF7-N55 breast cancer cells demonstrate upregulation of IL1B in response to 
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TRAP6 stimulation (Figure 16a and 16b, top left).  Further, PAR1 stimulation in MDA-MB-
231 and MCF7-N55 cells leads to upregulation of the inflammatory cytokine IL-8 (Figure 16a 
and 16b, bottom left) and of SERPINE1 (also referred to as PAI-1, Figure 16 a and 16b, 
bottom right), both of which are highly implicated in breast cancer metastasis.  Additionally, the 
parental MCF7 breast cancer line did not show expression of IL1B or IL8 when treated with 
TRAP6, as expected given the low PAR1 expression in this cell line (data not shown). 
Unlike in U2OS cells, we did not observe MMP9 expression when either MDA-MB-231 
or MCF7-N55 breast cancer cells were stimulated with a PAR1 agonist (Figure 16 and 16b, top 
right).   
 44 
 
Figure 16 – Breast cancer cells upregulate invasion-associated genes in response to PAR1 stimulation.  (a) 
IL1β, IL8, and SERPINE1 mRNA, though not MMP9 mRNA, is upregulated in MDA-MB-231 human breast cancer 
cells stimulated with 50 μM TRAP6 for 6 hours. (b) Similarly, in MCF7-PAR1 cells stimulated with 50 μM TRAP6 
for 6 hours, IL1β, IL8, and SERPINE1mRNA is upregulated. TRAP6 treatment did not affect MMP9 mRNA 
expression. 
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2.6 MALT1 KNOCKOUT SUPPRESSES PRO-METASTATIC GENE EXPRESSION 
IN BREAST CANCER 
2.6.1 CRISPR: generation of the N55-ΔMALT1 knockout pool 
In order to investigate the requirement for MALT1 in PAR1-induced gene expression changes, 
we used CRISPR230-234 to generate stable MCF7-N55 clones deficient in MALT1 (for 
methodological details, see section 4.8).  MALT1 knockout clones were identified by 
immunoblot; three MALT1 knockout clones were selected (4-2, 5-3, 6-5) and evenly pooled for 
use in experiments to avoid single-clone dependent observations.  This knockout pool is referred 
to as N55-ΔMALT1 below.  For use as a control, three clones of MCF7-N55 cells that 
underwent the CRISPR protocol but did not demonstrate detectable MALT1 knockout (as seen 
on immunoblot) were selected (5-2, 9-2, 12-1).  These clones were evenly pooled for 
experiments and are referred to as N55-Ctrl below.  All clones resulting from the CRISPR 
protocol were maintained separately in culture: N55-Ctrl and N55-ΔMALT1 pools were freshly 
prepared for each experiment.   
2.6.2 Validation of MALT1 knockout 
We regularly confirmed MALT1 knockout status in CRISPR clones by immunoblot and found 
that MALT1 knockout status remains stable for over six months following clonal selection 
(Figure 17, top panel).  Control CRISPR clones also demonstrated stable MALT1 expression 
over six months past single-clone selection.  . 
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Consistent with loss of MALT1, pooled N55-ΔMALT1 cells did not show 
phosphorylation of IκB when stimulated with TRAP6; whereas the N55-Ctrl pool demonstrated 
robust induction of pIκB when treated with TRAP6 (Figure 17, bottom panel). 
 
 
 
Figure 17 – Generation and validation of MALT1 
CRISPR knockout cells.  Confirmation that N55-∆MALT1 
cells are deficient in MALT1 (top panel), and fail to respond 
to TRAP6-mediated stimulation of PAR1 by inducing pIκB 
(bottom panel; cells treated with 50 μM TRAP6 for 20 
minutes). 
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2.6.3 MALT1 knockout suppresses IL1B and IL8 induction downstream of PAR1 in 
breast cancer 
The pooled N55-Ctrl cells behave similarly to the parental MCF7-N55 cells when stimulated 
with TRAP6 and assayed for gene expression reprogramming changes.  TRAP6 stimulation of 
N55-Ctrl cells induces expression of IL1B; however, N55-ΔMALT1 cells do not demonstrate 
IL1B induction under the same conditions (Figure 18, top left), suggesting that MALT1 is 
required for IL1B upregulation after PAR1 stimulation in a fashion similar to that observed in 
U2OS osteosarcoma cells.  Additionally, TRAP6 stimulation of N55-Ctrl cells induces IL8 
expression, again consistent with MDA-MB-231 cells, and MALT1 is required for this effect 
(Figure 18, bottom left).   
Additionally, we found that MMP9 is not upregulated in N55-Ctrl or in N55-ΔMALT1 
cells in response to TRAP6 stimulation (Figure 18, top right).  This is consistent with our 
observations in MDA-MB-231 breast cancer cells, giving us high confidence that MMP9 is not 
in fact expressed downstream of PAR1-associated NF-κB activation in breast cancer.  
Intriguingly, we noted that PAR1-induced SERPINE1 expression does not require MALT1 
(Figure 18, bottom right).  Stimulation of both N55-Ctrl cells and N55-ΔMALT1 with TRAP6 
induced similar amounts of SERPINE1 expression, indicating that SERPINE1 expression is 
likely PAR1-depdent but MALT1-independent in breast cancer. 
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Figure 18 – MALT1 is required for IL1B and IL8 expression downstream of PAR1 in breast cancer 
cells.  PAR1-dependent IL1β and IL8 mRNA upregulation is abrogated in N55-∆MALT1 cells as compared to N55-
Ctrl cells. MMP9 is not upregulated in response to PAR1 stimulation in N55-Ctrl or N55-∆MALT1 cells. PAR1-
dependent upregulation of SERPINE1 is not affected by MALT1 knockdown. Cells were stimulated with 50 μM 
TRAP6 for 6 hours. 
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2.7 MALT1 KNOCKOUT ATTENUATES IN VITRO INVASION 
AND IN VIVO METASTASIS 
2.7.1 Transwell assay of invasion 
After identification of a number of a pro-metastatic genes downstream of PAR1/CBM signaling, 
we sought to determine whether stimulation of this signaling axis had functional, phenotypic 
effects relevant to metastasis on human cancer cells.  We first asked whether MALT1 is required 
for PAR1-dependent invasion in vitro.  It has been previously shown that PAR1 expression 
specifically induces aggressive in vitro invasion and migration in the MCF7/MCF7-N55 
system29,132.  In a transwell chamber assay of in vitro invasion, we found a similar result in that 
PAR1-high MCF7-N55 cells invade through a collagen matrix at a significantly higher rate than 
the parental PAR1-low MCF7 cells (Figure 19a).   
We then asked whether MALT1 was required for this PAR1-specific induction of in vitro 
invasion.  We compared invasion of the N55-Ctrl pool to the N55-ΔMALT1 pool in the 
transwell invasion assay.  We found that N55-Ctrl cells invade similarly to the MCF7-N55 cells 
from which they were derived; however, in vitro invasion of N55-ΔMALT1 cells is substantially 
blunted relative to the N55-Ctrl pool.  Taken together these results suggest that MALT1 is 
required for the invasive cellular phenotype specifically induced by PAR1 expression (Figure 
18b). 
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Figure 19 – CRISPR knockout of MALT1 in MCF7-N55 cells attenuates invasion in vitro.  (a) MCF7-PAR1 
(PAR1-high) cells demonstrate significantly inceased invasion in a Boyden chamber transwell assay as compared to 
parental MCF7 (PAR1-low) cells.  (b) Pooled N55-∆MALT1 cells demonstrate significant loss of invasiveness as 
compared to pooled N55-Ctrl cells. 
 
2.7.2 Mouse model of breast cancer metastasis 
We then proceeded to compare the formation of lung metastasis using N55-Ctrl cells or N55-
ΔMALT1 cells in a tail-vein injection model.  See Appendix A for details of ongoing 
experiments. 
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2.8 PAR1 STIMULATION ACTIVATES MALT1 PROTEOLYTIC ACTIVITY IN 
SOLID TUMORS 
2.8.1 RelB: a target of the MALT1 protease 
We investigated whether PAR1 stimulation in cancer cells induces MALT1 proteolytic activity, 
specifically by testing for cleavage of the NF-κB family member RelB, a known substrate of 
MALT1189,191.  We found that stimulation of U2OS osteosarcoma cells with thrombin induces 
accumulation over time of a RelB cleavage fragment detectable by immunoblot (Figure 20a).   
We then looked to breast cancer, examining whether PAR1 stimulation-associated 
MALT1 cleavage of RelB could be detected in MDA-MB-231 cells.  In MDA-MB-231 cells, we 
found that TRAP6 stimulation induces generation of a RelB cleavage fragment (Figure 20b).  
As expected, no RelB cleavage is observed upon TRAP6 treatment of parental MCF7 cells, 
which do not express appreciable levels of PAR1.  In contrast, TRAP6 -induced RelB cleavage is 
readily detected in MCF7-N55 cells (Figure 21b).   
All of the RelB cleavage experiments performed above were carried out in the presence 
of the proteasome inhibitor MG132 in order to increase RelB cleavage fragment detection.  RelB 
cleavage fragments were rapidly cleared from the cell by proteasomal degradation without 
MG132, consistent with published reports in lymphoma cell lines191. 
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Figure 20 – PAR1 stimulation activates MALT1 proteolytic activity in solid tumors.  (a) U2OS human 
osteosarcoma cells were stimulated with 25 μM TRAP6 for the indicated times.  A RelB proteolytic cleavage 
fragment of approximately 40 kD can be seen accumulating (arrowhead).  (b) RelB proteolytic cleavage also occurs 
in MDA-MB-231 breast cancer cells stimulated with thrombin, and treatment with the MALT1 inhibitor, MI-2, 
suppresses RelB cleavage. Cells were pretreated with 2 μM MI-2 or DMSO vehicle before treatment with 2 U / mL 
thrombin for 3 hours.  All experiments above were performed in the presence of the proteasome inhibitor MG132 to 
prevent proteasomal degradation of the RelB cleavage fragment. 
2.8.2 RelB degradation in osteosarcoma and breast cancer is MALT1-specific 
In order to determine whether the detected cleavage of RelB was in fact MALT1 specific, we 
utilized two specific inhibitors of the MALT1 protease: ZVRPR-fmk, a covalently-bonding 
irreversible peptide inhibitor that binds to the MALT1 active site, or MI-2, an irreversible suicide 
substrate small molecule inhibitor of MALT1 proteolytic activity149,235.  Thrombin stimulation-
induced cleavage of RelB in U2OS cells was suppressed in a concentration-dependent manner by 
both ZVRPR-fmk and MI-2 (Figure 21a), strongly suggesting that PAR1 stimulation is 
activating MALT1 proteolysis of RelB in osteosarcoma. 
Additionally, MI-2 treatment of MDA-MB-231 (Figure 20b) and MCF7-N55 (Figure 
21b) cells stimulated with TRAP6 suppressed generation of a RelB cleavage fragment, 
suggesting that RelB cleavage in breast cancer cells is also MALT1-specific.  Further, the N55-
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Ctrl pool of CRISPR clones with intact MALT1 demonstrated generation of a RelB cleavage 
fragment when stimulated with TRAP6; however, the MALT1-deficient N55-ΔMALT1 pool lost 
RelB cleavage, indicating that MALT1 is required for RelB cleavage in breast cancer cells.   
 
 
 
Figure 21 – Cleavage of RelB in osteosarcoma and breast cancer is MALT1-specific.  (a)  The MALT1-protease 
inhibitors ZVRPR-fmk and MI-2 both suppress the formation of the RelB cleavage fragment in a dosage-dependent 
manner in U2OS osteosarcoma cells.  Cells were pretreated with the indicated concentrations of inhibitor for 1 hour 
before stimulation with 2 U / mL thrombin for 3 hours.  (b)  MALT1 dependent RelB cleavage occurs after PAR1 
stimulation in MCF7-PAR1 cells, but not in control parental MCF7 cells.  Cells were pretreated without or with 2 
μM MI-2 before treatment with 50 μM TRAP6 for 3 hours.  (c)  CRISPR knockout of MALT1 suppresses RelB 
cleavage fragment formation after TRAP6 stimulation.  N55-Ctrl and N55-ΔMALT1 cells were treated with 50 μM 
TRAP6 for 3 hours with MG132.  All experiments above were performed in the presence of the proteasome 
inhibitor MG132 to prevent proteasomal degradation of the RelB cleavage fragment. 
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We asked whether MALT1 proteolytic activity inhibition had any effect on gene 
expression, so we next treated U2OS cells with the MALT1 protease activity inhibitors ZVRPR-
fmk or MI-2.  We found that PAR1-dependent induction of both IL1B (Figure 22a) and MMP9 
(Figure 22b) are blocked by both MALT1 protease inhibitors. 
Taken together, our results indicate that in both osteosarcoma and breast cancer cells, 
MALT1 proteolytic activity is induced by PAR1 stimulation, providing the first evidence of 
MALT1 proteolytic activity in non-hematopoietic tumors and further confirming PAR1-induced 
MALT1 activation in these malignant cells. 
 
 
Figure 22 – MALT1 proteolytic activity is required for PAR1 stimulation-induced expression of IL1B and 
MMP9.  MALT1 protease inhibitors ZVRPR and MI-2 suppress PAR1-dependent upregulation of (a) MMP9 and 
(b) IL1β. Cells were pretreated with 25 μM ZVRPR-fmk or 2 μM MI-2 for one hour before stimulation with 2 U / 
mL thrombin for 6 hours. 
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3.0  DISCUSSION 
In this work, we show that the CBM complex is a critical mediator of PAR1-induced signaling to 
NF-κB.  Our bioinformatics findings demonstrate that patients with high tumor PAR1 expression 
have worse clinical outcomes (Figures 6a and 7a).  Further, we note that the CBM complex is 
required for PAR1 activation of NF-κB in both endogenous (MDA-MB-231, U2OS) and ectopic 
(MCF7-N55) systems of PAR1 expression, giving us confidence that our findings are 
representative of PAR1 signaling in cancer more broadly and not due solely to cell line and/or 
tumor type-specific factors.  We demonstrate a requirement for MALT1 in PAR1-driven 
expression of genes tightly associated with metastasis: IL1β and MMP9 in osteosarcoma and 
IL1β and IL8 in breast cancer.  Further, we show that MALT1 knockout attenuates in vitro 
invasion driven by PAR1 expression. 
3.1 PAR1, CBM, AND NF-ΚB SIGNALING IN OSTEOSARCOMA 
AND BREAST CANCER METASTASIS 
Our results show that PAR1 signaling activates NF-κB and promotes invasion through the CBM 
complex in tumor cells; however, this pro-metastatic behavior is not due to constitutively 
activating oncogenic mutations at any point in the signaling pathway, rather, it is due to 
endogenous PAR1 signaling that inappropriately activates inflammation.  Taken together, these 
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results point to possible mechanisms by which the CBM complex mediates pro-metastatic 
signaling in cancer.   
NF-κB activation, such as the activation we describe downstream of PAR1 / CBM 
signaling, promotes metastasis in myriad ways209.  First, NF-κB stimulates cell proliferation and 
protects against apoptosis directly through upregulation of a variety of survival factors and tissue 
invasion effectors, such as cIAP and MMPs211.  Second, NF-κB induction is associated with 
MMP expression and tissue invasion213.  Third, NF-κB activation is tightly linked with the 
expression of EMT markers such as Twist and Snail214,215.  Fourth, NF-κB signaling has been 
implicated in the expression of cellular adhesion proteins, necessary in the vascular extravasation 
step of metastasis.  Given that pharmacological NF-κB suppression can attenuate osteosarcoma 
and breast cancer proliferation and invasion, it is likely that NF-κB plays an important role in the 
promotion of metastasis in these two cancers. 
With our observation that PAR1-CBM signaling leads to activation of NF-κB in 
osteosarcoma and breast cancer, suppression of CBM signaling should block any contribution of 
PAR1 to NF-κB-mediated metastasis in these tumors.  It is important to note that our results 
should not be interpreted beyond the extent of the PAR1 – CBM – NF-κB signaling axis.  There 
are numerous pathways that can result in PAR1-independent and CBM-independent NF-κB 
activation, or indeed NF-κB-independent metastasis.  We observed TNFa stimulation induction 
of pIκB, indicating NF-κB activation, independent of the CBM complex in both breast cancer 
and osteosarcoma.  However, our results showing that PAR1 expression predicts poor outcome 
for osteosarcoma and breast cancer patients (Figures 6a and 7a), as well as previous reports 
indicating that PAR1 expression correlates with severity of disease, give us confidence that, 
while the PAR1 may not be the only cell surface receptor that can lead to NF-κB activation and 
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promotion of metastasis in these cancers, it is nevertheless an important contributor to tumor 
metastasis. 
3.2 ADDING TO THE MODEL OF THE CBM COMPLEX IN SOLID TUMORS 
An emerging model of the CARMA3-containing CBM complex as a putative “central hub” of 
GPCR activation of NF-κB promises exciting developments for future clinical and basic 
research.  Several GPCRs, most notably AGTR1236, CXCR4180, LPA receptors199, and now 
PAR1 have been demonstrated to activate NF-κB and promote solid tumor progression and 
metastasis via the CBM complex, and it seems likely that other GPCRs which engage the CBM 
complex in promoting NF-κB dependent tumor metastasis will be identified in the future.  
Several enticing questions remain unanswered, such as to what extent the CBM complex is 
capable of integrating intracellular signaling from multiple upstream GPCRs and whether multi-
GPCR activation of CBM signaling has an additive effect on NF-κB activation and metastasis 
promotion.  The position of the CBM complex as a common step in the intracellular signaling 
pathway that leads from cell surface receptors to NF-κB activation in cancer makes it an 
attractive therapeutic target: pharmacologically knocking out CBM signaling could, in theory, 
suppress pro-metastatic signals from multiple GPCRs. 
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3.3 MALT1 PROTEOLYTIC ACTIVITY: A POTENTIAL THERAPEUTIC TARGET 
3.3.1 Clinical significance of this work 
Our results suggest that MALT1 proteolytic activity inhibition could attenuate inappropriate 
PAR1-driven activation of NF-κB in solid tumors in order to prevent or treat metastatic disease.  
MALT1 protease activity inhibitors are currently in preclinical development.  Thus far, three 
categories of MALT1 protease inhibitors are in active research use: modified peptides, small 
molecules, and phenothiazines.  Modified peptides such as ZVRPR-fmk149, and small molecules 
like MI-2235, are irreversible inhibitors that covalently bond with MALT1.  Most intriguingly 
from a preclinical standpoint, several phenothiazines, an FDA-approved class of antipsychotics, 
have recently been shown to reversibly inhibit MALT1 proteolytic capability at low 
concentrations237.  Excitingly, several MALT1 inhibitors, including MI-2235 and the 
phenothiazine derivatives mepazine238,239 and thioridizine237, have successfully been used to treat 
mice in models of disease with little observed toxicity.   
Our evidence suggests that upregulation of metastasis-associated genes such as MMP9 
and IL1B downstream of PAR1 stimulation in osteosarcoma are suppressed by treatment with 
these MALT1 inhibitors (Figure 22).  Through downregulation of these important pro-metastatic 
targets, MALT1 proteolytic activity inhibition may decrease metastatic behavior in 
osteosarcoma, though this has yet to be demonstrated.   
The majority of osteosarcoma patients do not present with clinically identifiable 
metastatic disease, and development of metastases during treatment has catastrophic prognostic 
consequences.  It is possible that the addition of a MALT1 proteolytic activity inhibitor to the 
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current MAP protocol of adjuvant / neo-adjuvant chemotherapy in combination with surgery 
may serve to prevent the development of metastases in these at-risk patients. 
3.3.2 Future applications of MALT1 inhibition in solid tumor treatment 
Successful treatment of solid tumors in which CBM signaling is involved will require multiple 
modalities and strategies.  It is doubtful that MALT1 inhibition alone will be enough to suppress 
cancer growth and progression sufficiently such that it could be used as a single-agent treatment 
for solid tumors.  Similar to the current standard of osteosarcoma and breast cancer care in which 
multiple chemotherapeutics are used to treat an individual patient’s disease, MALT1 proteolytic 
activity inhibition could be employed in combination with other targeted therapies, such as NF-
κB suppression, to more effectively inhibit cancer progression.  Selective NF-κB inhibition has 
long been sought after for use as an anticancer therapeutic; however, difficulties in limiting 
patient immunosuppression have hampered drug development efforts240.  As part of a multi-
agent protocol along with a MALT1 proteolytic activity inhibitor, though, it is possible that 
milder NF-κB suppression could be used to effectively target pathways that promote the growth 
and metastasis of CBM-associated solid tumors. 
3.4 POSSIBLE FUTURE DIRECTIONS 
As with many research projects, a surfeit of fascinating and compelling questions are raised by 
our results.  Possible future research directions arising from this project are discussed below. 
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Our observation that PAR1 – CBM – NF-κB signaling in cancer cells induces the 
expression of several inflammatory cytokines such as IL1B and IL8 suggests the possible 
existence of an autocrine or paracrine positive-feedback loop in which initial NF-κB signaling 
events drive transcription, translation, and secretion of further inflammatory mediators.  These 
inflammatory mediators may go on to trigger even more NF-κB activation in tumor cells and in 
the stromal microenvironment, making the tumor cells and microenvironment more metastatic or 
permissive of metastasis.  The nature and extent of such CBM-mediated tumor / 
microenvironmental interactions has yet to be described; however, elucidation CBM complex-
mediated tumor-stroma interaction would be a novel finding in the field of CBM cancer research. 
NF-κB is not the sole downstream output of either PAR1 or of the CBM complex itself.  
The CBM complex is known to trigger JNK signaling192, itself a pro-metastatic signaling 
pathway: JNK activation has been shown to increase sensitivity to chemotherapeutics in 
osteosarcoma241.  The role of CBM-mediated signaling pathways aside from NF-κB and their 
contributions to solid tumor metastasis is an enticing research questions that has not been directly 
addressed in the literature. 
Our results indicate a possible role for MALT1 proteolytic activity inhibition in the 
suppression of pro-metastatic genes in solid tumors; however, substantially more work on the 
effects of MALT1 proteolytic activity inhibition in solid tumors remains.  While we see evidence 
for MALT1-mediated cleavage of RelB, it is only one of a variety of known MALT1 substrates 
(Table 2).  It is not known whether MALT1 proteolytic activity degrades other targets in solid 
tumors and what, if any, effects that proteolytic cleavage has on pro-metastatic behavior in 
osteosarcoma and breast cancer. 
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3.5 CONCLUSIONS 
The work described herein shows a clear role for CBM complex-mediated NF-κB activation in 
the promotion of breast cancer and osteosarcoma metastasis.  We show that PAR1-driven 
expression of several pro-metastatic genes requires MALT1, and that suppression of MALT1 
impairs PAR1-associated invasion in vitro.  In addition to our findings demonstrating MALT1-
mediated NF-κB activation downstream of PAR1 stimulation in these solid tumors, we present 
the first evidence of MALT1 proteolytic activity observed in non-lymphoid cancer: an exciting 
development in the field of CBM complex signaling in solid tumors, as MALT1 proteolytic 
activity represents a promising future therapeutic target.  It our profound hope that, through the 
elucidation and investigation of the mechanistic pathways that drive cancer metastasis, new 
therapies and novel strategies will be found to aid in the treatment of this debilitating facet of 
cancer. 
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4.0  MATERIALS AND METHODS 
4.1 CLINICAL DATA ANALYSIS AND STATISTICS 
Publicly available gene expression data were obtained from Kelly et al.225 (osteosarcoma) and 
TCGA226 (breast cancer).  Statistical analyses were performed using the Graphpad Prism (v7.01) 
software package.  Kaplan-Meier P values were calculated using the Mantel-Cox log-rank test.  
Other P values were calculated using the Student t test (two sided) or by analysis of one-way 
ANOVA, followed by Bonferroni posttest as appropriate. 
4.2 CELL LINES AND CULTURE 
U2OS human osteosarcoma cells and MDA-MB-231 human breast cancer cells were obtained 
from the ATCC (Manassas, VA).  MCF7 and MCF7-N55 human breast cancer cells were a kind 
gift from L. Covic of Tufts University (Boston, MA).  U2OS and MDA-MB-231 cells were 
cultured in DMEM with GlutaMAX (Gibco) supplemented with 10% FBS and 1% streptomycin 
/ penicillin.  MCF7 and derivatives were cultured in phenol red-free RPMI 1640 (Gibco) with 
10% FBS and 1% streptomycin / penicillin.  Cell lines were regularly tested for Mycoplasma 
contamination using the MycoAlert Mycoplasma detection assay (Lonza, Allendale, NJ). 
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4.3 REAGENTS 
TRAP6 and ZVRPR-fmk were purchased from AnaSpec (Fremont, CA).  Thrombin was 
obtained from Enzo Life Sciences (Farmingdale, NY).  TNFa and MG132 were from Sigma-
Aldrich (St. Louis, MO).  MI-2 was procured from R&D Systems (Minneapolis, MN). 
4.4 NUCLEAR FRACTIONATION AND ELISA 
Nuclear isolates were generated using the Active Motif (Carlsbad, CA) Nuclear Extract Kit 
according to manufacturer’s instructions.  Nuclear fractions were subjected to Immunoblot 
analysis as below, or tested for NF-κB subunit activation using TransAM NF-κB family ELISA 
kit (Active Motif). 
4.5 LUCIFERASE REPORTER ASSAY 
NF-κB firefly luciferase and transfection control renilla luciferase plasmids were procured from 
Agilent Technologies (Santa Clara, CA).  Plasmids were forward-transfected into cells using 
lipofectamine 3000 and PLUS reagent (Thermo Fisher Scientific).  Cells were stimulated 24 
hours post-transfection and luciferase induction was evaluated using a microplate luminometer. 
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4.6 IMMUNOBLOT ANALYSIS 
Cells were placed in serum-free medium for 4h prior to stimulation.  After stimulation (see 
individual experiments for details) immunoblot analysis was performed as described 
previously176.  Lysate protein content was determined by bicinchoninic acid assay.  Antibodies 
used in our studies are detailed in Table 3 (CST: Cell Signalling Technologies, Danvers, MA; 
Santa Cruz Biotech, Santa Cruz, CA; GeneTex, Irvine, CA). 
 
Table 3. List of antibodies used. 
Antigen Source Catalogue Number 
RelB CST 4922 
MALT1 CST 2494 
CARMA3 GeneTex 111222 
Bcl10 Santa Cruz Biotech Sc-9560 
pIκB CST 9240 
GAPDH CST 5174 
Actin CST 4970 
HDAC1 CST 5356 
Tubulin CST 5335 
2o mouse CST 7070 
2o rabbit CST 7074 
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4.7 RT-PCR AND INVASION PCR MICROARRAY 
RNA isolation and cDNA generation was performed as described in182.  Quantitative PCR was 
performed using TaqMan probes and reagents (Thermo Fisher Scientific).  A custom 96-well 
RT-PCR array was procured from Thermo Fisher Scientific.  The MORPHEUS matrix 
visualization and analysis tool was used to generate and process heat maps242. 
4.8 GENERATION OF N55 -ΔMALT1 
Human MALT1 CRISPR targets were identified using the GeneArt CRISPR Seach and Design 
tool (Thermo Fisher Scientific).  The GeneArt Precision gRNA Synthesis Kit (Thermo Fisher 
Scientific), GeneArt Platinum Cas9 Nuclease, and Lipofectamine CRISPRMAX Reagent were 
used according to manufacturer instructions.  Following single-clone expansion, MALT1 
knockout was verified by immunoblotting.  The GeneArt Genomic Cleavage Detection Kit was 
utilized to detect CRISPR cleavage products. 
4.9 SIRNA KNOCKDOWN 
SMARTpool siRNA pools directed against MALT1, Bcl10, CARMA3, and scramble control 
were generated by GE Dharmacon (Lafayette, CO).  Cells were reverse-transfected with siRNA 
using lipofectamine RNAiMAX (Thermo Fisher Scientific, Waltham, MA).  Cells were allowed 
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to incubate for 72 hours after transfection before stimulation or assays.  Knockdown efficiency 
was determined by immunoblot or RT-PCR. 
 
Table 4. siRNA sequences used. 
Target siRNA Sequences 
Control 
UGGUUUACAUGUCGACUAA 
UGGUUUACAUGUUGUGUGA 
UGGUUUACAUGUUUUCUGA 
UGGUUUACAUGUUUUCCUA 
CARMA3 
CAGAUGGACUGUCGUUUUA 
GCGUGUGGCCUUUGGGAAA 
CMGAGAUCCUUCGACUGG 
GAACUCGGCUGUACUUCGC 
Bcl10 
GCCACCAGAUCUACAGUUA 
CGAACAACCUCUCCAGAUC 
GGGCAUCCACUGUCAUGUA 
AAUCAUAGCUGAGAGACAU 
MALT1 
GGGAGUAUAUGGGUUAUUA 
GCAGUGUUCUCUUAAGGUA 
GCAAAUCUGUGUUGAACCA 
GGUAAUCCAAGUAAUGUUA 
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4.10 IN VITRO INVASION ASSAY 
Transwell chamber invasion assays were performed as described previously243,244.  Transwell 
inserts were imaged using an EVOSfl digital inverted microscope (Thermo Fisher Scientific) and 
manually quantified by averaging the total cells in 5 fields.  Each condition was performed in 
duplicate per experiment and each experiment was performed in triplicate. 
4.11 MOUSE MODEL OF METASTASIS AND IMAGING 
Mouse metastasis studies were performed as described previously132.  2*106 of N55-Ctrl or N55 
-ΔMALT1 cells were injected into the lateral tail vein of 8 week old female NCr athymic nu/nu 
mice (Taconic Farms, Hudson, NY).  All animal experiments and procedures were performed in 
full compliance with the University of Pittsburgh Institutional Animal Care and Use Committee.  
A Siemens (Berlin, Germany) Inveon micro-CT at the Children’s Hospital of Pittsburgh animal 
imaging core laboratory was used to perform thoracic-CT on mice anesthetized using 
isofluorane.  Image interpretation was performed by a clinical radiologist from the UPMC 
Presbyterian Hospital Department of Radiology in a randomized and interpreter-blinded fashion. 
 68 
APPENDIX A 
ONGOING EXPERIMENTS 
A.1 MOUSE MODEL OF BREAST CANCER METASTASIS 
In order to examine the requirement of MALT1 in PAR1-driven cancer metastasis, we are 
utilizing the CRISPR-modified MCF7-N55 system.  It has been previously shown that PAR1 
expression in MCF7-N55 cells specifically drives metastasis in vivo.  MCF7-N55 cells rapidly 
colonize the lungs of mice in a tail vein injection xenograft model of metastasis; whereas both 
parental MCF7 cells and MCF7-R310E cells do not.  MCF7-R310E are MCF7 cells which have 
been engineered to express PAR1 with a single point mutation that renders intracellular signaling 
inoperative (ie thrombin proteolysis of the PAR1-R310E N-terminal ligand has no downstream 
signaling effects)132. 
To test for MALT1 requirement of PAR1-driven metastasis, we used the N55-Ctrl and 
N55-ΔMALT1 CRISPR clone pools described in section 2.6 above.  We injected 2*106 cells of 
freshly made, evenly pooled N55-Ctrl cells or N55-ΔMALT1 cells into the lateral tail veins of 8 
week old female athymic nude mice (Figure 23).  We are monitoring tumor development in the 
mice with regular examination and weight tracking, along with micro-CT imaging to visualize 
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developing pulmonary metastases.  CT image sets are being evaluated by a clinical radiologist 
from the UPMC department of Radiology. 
Whereas the MCF7-N55 cells appeared to colonize nude mouse lungs over the course of 
6 weeks in a published paper132, our initial cohort of N55-Ctrl mice – the mice injected with cells 
that we expect to be closest in behavior to the rapidly metastatic MCF7-N55 cells – has 
demonstrated an irregular pattern of death from disease.  Two N55-Ctrl-injected mice were 
required to be sacrificed due to large subcutaneous tumor growth: one mouse grew a 2 x 1.5 cm 
tumor dorsally near the hind limbs, while the other had a 1.5 cm x 1 cm cervical tumor.  The 
lungs of both of these mice were grossly metastasis-free upon examination after resection.  In 
addition to these two events, one mouse in the N55-Ctrl cohort did die of pulmonary metastatic 
disease (Figure 24).  Two mice in the N55-Ctrl cohort, as well as all 5 mice in the N55-
ΔMALT1 cohort, are apparently healthy and disease-free almost 20 weeks post-injection. 
Given that MCF7-N55 cells metastasize and colonize nude mice lungs in 6 weeks or less, 
and given the substantial amount of time our initial cohort has continued post-injection, we 
thought to repeat this experiment using a larger cohort: 10 mice injected with N55-Ctrl and 10 
injected with N55-ΔMALT1.  After identification of metastatic disease using micro-CT, lungs of 
these mice will be resected, fixed, and stained using hematoxylin and eosin staining to count 
metastases.  We expect that N55-ΔMALT1-injected mice will have lungs with fewer metastases 
relative to the N55-Ctrl-injected mice. 
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Figure 23 – Schematic overview of mouse experiment of breast cancer metastasis. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24 – Preliminary results from ongoing mouse experiment.  (a) Micro-CT image of N55-Ctrl-
injected mouse demonstrating identifiable pulmonary metastases (white arrows).  (b)  Photograph of lung from (a) 
immediately post-resection.  Metastases are grossly visible (black arrows). 
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APPENDIX B 
LIST OF ABBREVIATIONS AND NOMENCLATURE USED 
Anoikis  Apoptosis triggered by loss of contacts to neighboring cells or 
extracellular matrix 
Bcl10  Linker protein that binds to both CARMA and MALT1 
Bcl-xL  Survival factor 
BRCA1  Hereditary breast cancer marker 
BRCA2  Hereditary breast cancer marker 
CARD  Caspase activation and recruitment domain 
CARMA1  (CARD11) Scaffolding protein that brings together the CBM, found in 
 lymphoid cells 
CARMA2  (CARD14) Scaffolding protein that brings together the CBM, found in 
 placenta 
CARMA3  (CARD10) Scaffolding protein that brings together the CBM, found in 
 non-lymphoid cells 
CBM  Signaling complex composed of CARMA proteins, Bcl10, and MALT1 
CDH1  E-cadherin 
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CDH2  N-cadherin 
cIAP2  Inhibitor of apoptosis 2, survival factor 
CRISPR  Clustered regularly interspaced short palindromic repeats, gene 
 modification and knockout technology 
CXCR4  Chemokine receptor, linked to CBM activation of NF-κB 
EGFR  Epidermal growth factor receptor 1 
EMT  Epithelial-mesenchymal transition 
ER  Estrogen receptor 
ECM  Extracellular matrix, the non-cellular organic components of tissue 
Extravasation  Invasion of tumor cells through the endothelial barrier to exit the 
 circulation at a distant site 
GPCR  G-protein coupled receptor 
HER2  Epidermal growth factor receptor 2 
IκB  Inhibitor of κB 
IKK  Complex that phosphorylates IκB to activate canonical NF-κB signaling 
Intravasation  Invasion of tumor cells through the endothelial barrier into the blood 
 circulation 
LPA  Lysophosphatidic acid 
LUBAC  Linear ubiquitination assembly complex 
MAGUK  Membrane associated guanylate kinase like domain 
MALT1  Effector protein of the CBM complex through protein-protein interactions 
 with and proteolytic degradation of downstream signaling mediators 
Metastasis  The process by which cancer spreads from one organ to another 
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MMP  Matrix metalloproteinase 
NF-κB  transcription factor family associated with inflammation 
NIK  NF-κB inducing kinase, mediates non-canonical activation of NF-κB 
P100  Precursor that is cleaved into p52 
PAR1  Protease activated receptor 1 
PDGF  Platelet derived growth factor 
PKC  Protein kinase C, isoforms of which are responsible for CARMA 
 phosphorylation 
PR  Progesterone receptor 
RB1  Retinoblastoma tumor suppressor 
TAK1  Intracellular kinase important in IKK complex activation 
TF  Tissue factor, cell surface mediator of the coagulation cascade 
Thrombin  Serine protease central to the coagulation cascade 
TP53  Tumor suppressor 
TRAF6  Ubiquitin ligase important in IKK complex activation 
VEGF  Vascular endothelial growth factor, important in angiogenesis 
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